Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

McVay CS, Rolfe RD.

Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8.

2.

Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Anton PM, O'Brien M, Kokkotou E, Eisenstein B, Michaelis A, Rothstein D, Paraschos S, Kelly CP, Pothoulakis C.

Antimicrob Agents Chemother. 2004 Oct;48(10):3975-9.

3.

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NC, Fernandes PB, Clement JJ.

Antimicrob Agents Chemother. 1991 Jun;35(6):1108-11.

4.

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.

Freeman J, Baines SD, Jabes D, Wilcox MH.

J Antimicrob Chemother. 2005 Oct;56(4):717-25. Epub 2005 Sep 5.

PMID:
16143709
5.

Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.

Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ; ECDIS Study Group.

J Antimicrob Chemother. 2013 Jun;68(6):1305-11. doi: 10.1093/jac/dkt013. Epub 2013 Feb 18.

PMID:
23420839
6.

Efficacy of LFF571 in a hamster model of Clostridium difficile infection.

Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D.

Antimicrob Agents Chemother. 2012 Aug;56(8):4459-62. doi: 10.1128/AAC.06355-11. Epub 2012 May 29.

7.

Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Warren CA, van Opstal E, Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I, Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4103-11. doi: 10.1128/AAC.00360-12. Epub 2012 May 14.

8.

Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.

Warren CA, van Opstal EJ, Riggins MS, Li Y, Moore JH, Kolling GL, Guerrant RL, Hoffman PS.

Antimicrob Agents Chemother. 2013 Feb;57(2):689-96. doi: 10.1128/AAC.00877-12. Epub 2012 Nov 12.

9.

Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile.

Nagaro KJ, Phillips ST, Cheknis AK, Sambol SP, Zukowski WE, Johnson S, Gerding DN.

Antimicrob Agents Chemother. 2013 Nov;57(11):5266-70. doi: 10.1128/AAC.00580-13. Epub 2013 Aug 12.

10.

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.

Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ.

J Antimicrob Chemother. 2007 Apr;59(4):705-10. Epub 2007 Mar 2.

PMID:
17337513
11.

Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters.

Merrigan MM, Sambol SP, Johnson S, Gerding DN.

J Infect Dis. 2003 Dec 15;188(12):1922-7. Epub 2003 Dec 9.

PMID:
14673773
12.

New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration.

Merrigan MM, Sambol SP, Johnson S, Gerding DN.

Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S46-50. doi: 10.1016/S0924-8579(09)70017-2.

PMID:
19303570
13.

Nitazoxanide for the treatment of Clostridium difficile colitis.

Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, Rossignol JF.

Clin Infect Dis. 2006 Aug 15;43(4):421-7. Epub 2006 Jul 11.

PMID:
16838229
14.

In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.

Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W.

Antimicrob Agents Chemother. 2014;58(2):892-900. doi: 10.1128/AAC.01830-13. Epub 2013 Nov 25.

15.

[Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002].

Pituch H, Obuch-Woszczatyński P, Glinka D, Łazińska B, Meisel-Mikołajczyk F, Łuczak M.

Med Dosw Mikrobiol. 2003;55(3):253-8. Polish.

PMID:
14702667
16.

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ.

Clin Infect Dis. 2008 Jul 1;47(1):56-62. doi: 10.1086/588293.

PMID:
18491964
17.

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Nelson R.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004610. Review. Update in: Cochrane Database Syst Rev. 2011;(9):CD004610.

PMID:
17636768
18.

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.

Ochsner UA, Bell SJ, O'Leary AL, Hoang T, Stone KC, Young CL, Critchley IA, Janjic N.

J Antimicrob Chemother. 2009 May;63(5):964-71. doi: 10.1093/jac/dkp042. Epub 2009 Feb 26.

PMID:
19251726
19.

Antibacterial activity of teicoplanin against Clostridium difficile.

Wongwanich S, Kusum M, Phan-Urai R.

Southeast Asian J Trop Med Public Health. 1996 Sep;27(3):606-9.

PMID:
9185278
20.

In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.

Kumar M, Mathur T, Barman TK, Ramkumar G, Bhati A, Shukla G, Kalia V, Pandya M, Raj VS, Upadhyay DJ, Vaishnavi C, Chakrabarti A, Das B, Bhatnagar PK.

Antimicrob Agents Chemother. 2012 Nov;56(11):5986-9. doi: 10.1128/AAC.00015-12. Epub 2012 Aug 6.

Supplemental Content

Support Center